INSM vs. QGEN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at INSM and QGEN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | INSM | QGEN |
|---|---|---|
| Company Name | Insmed Incorporated | Qiagen N.V. |
| Country | United States | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 27.36 billion USD | 10.67 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | June 1, 2000 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of INSM and QGEN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | INSM | QGEN |
|---|---|---|
| 5-Day Price Return | 1.33% | 0.49% |
| 13-Week Price Return | 90.70% | 14.95% |
| 26-Week Price Return | 64.55% | 22.82% |
| 52-Week Price Return | 66.84% | 4.79% |
| Month-to-Date Return | 20.67% | -0.28% |
| Year-to-Date Return | 87.50% | 10.49% |
| 10-Day Avg. Volume | 3.76M | 1.22M |
| 3-Month Avg. Volume | 3.46M | 1.45M |
| 3-Month Volatility | 65.51% | 21.16% |
| Beta | 1.03 | 0.68 |
Profitability
Return on Equity (TTM)
INSM
-195.37%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
INSM has a negative Return on Equity of -195.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
QGEN
10.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
QGEN’s Return on Equity of 10.66% is on par with the norm for the Life Sciences Tools & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
INSM
-259.82%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
INSM has a negative Net Profit Margin of -259.82%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
QGEN
18.30%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
A Net Profit Margin of 18.30% places QGEN in the upper quartile for the Life Sciences Tools & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
INSM
-252.41%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
INSM has a negative Operating Profit Margin of -252.41%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
QGEN
22.84%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
An Operating Profit Margin of 22.84% places QGEN in the upper quartile for the Life Sciences Tools & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | INSM | QGEN |
|---|---|---|
| Return on Equity (TTM) | -195.37% | 10.66% |
| Return on Assets (TTM) | -49.49% | 6.40% |
| Net Profit Margin (TTM) | -259.82% | 18.30% |
| Operating Profit Margin (TTM) | -252.41% | 22.84% |
| Gross Profit Margin (TTM) | 75.72% | 63.73% |
Financial Strength
Current Ratio (MRQ)
INSM
6.68
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
INSM’s Current Ratio of 6.68 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
QGEN
1.61
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
QGEN’s Current Ratio of 1.61 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
INSM
0.45
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
INSM’s Debt-to-Equity Ratio of 0.45 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
QGEN
0.41
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
QGEN’s Debt-to-Equity Ratio of 0.41 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
INSM
-27.79
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
INSM has a negative Interest Coverage Ratio of -27.79. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
QGEN
27.84
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
QGEN’s Interest Coverage Ratio of 27.84 is in the upper quartile for the Life Sciences Tools & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | INSM | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 6.68 | 1.61 |
| Quick Ratio (MRQ) | 6.13 | 1.19 |
| Debt-to-Equity Ratio (MRQ) | 0.45 | 0.41 |
| Interest Coverage Ratio (TTM) | -27.79 | 27.84 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
QGEN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
INSM
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INSM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
QGEN
0.00%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
QGEN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | INSM | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
INSM
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for INSM is currently unavailable.
QGEN
28.51
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
QGEN’s P/E Ratio of 28.51 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
INSM
68.25
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
INSM’s P/S Ratio of 68.25 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
QGEN
5.22
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
QGEN’s P/S Ratio of 5.22 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
INSM
15.28
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
INSM’s P/B Ratio of 15.28 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
QGEN
2.97
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
QGEN’s P/B Ratio of 2.97 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | INSM | QGEN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 28.51 |
| Price-to-Sales Ratio (TTM) | 68.25 | 5.22 |
| Price-to-Book Ratio (MRQ) | 15.28 | 2.97 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 21.47 |